Power-Trialysis Dialysis Catheters Recall Issued by Bard Access Systems
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Bard Access Systems, Inc. is recalling 8,795 units of Power-Trialysis Short-Term Dialysis Catheters due to a supplier recall of associated lidocaine ampoules.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on August 8, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Devices.
What Happened
Bard Access Systems, Inc. initiated a recall of specific lots of Power-Trialysis Short-Term Dialysis Catheters because lidocaine ampoules included with the devices were manufactured under deficient manufacturing practices by the supplier.
Which Products Are Affected
The recall covers 8,795 units distributed worldwide, including U.S. nationwide distribution to states AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, WA, WI, WV, and WY, as well as Belgium. Affected products and lots include:
- 5605150 Power-Trialysis Short-Term Straight Dialysis Catheter 13 Fr Triple-Lumen (UDI-DI: 00801741086953), Lot REKX1755
- 5605240 Power-Trialysis Short-Term Straight Dialysis Catheter 13 Fr Triple-Lumen (UDI-DI: 00801741086977), Lot REKW0663
- 5605300 Power-Trialysis Short-Term Straight Dialysis Catheter 13 Fr Triple-Lumen (UDI-DI: 00801741086984), Lot REKY2472
- 5615120 Power-Trialysis Short-Term Curved Extension Dialysis Catheter 13 Fr Triple-Lumen (UDI-DI: 00801741075087), Lot REKZ0393
- 5615200 Power-Trialysis Short-Term Curved Extension Dialysis Catheter 13 Fr Triple-Lumen (UDI-DI: 00801741075100), Lots REKQ1130, REKX3745, REKY2418
- 5655120 Power-Trialysis Short-Term Alphacurve Dialysis Catheter 13 Fr Triple-Lumen (UDI-DI: 00801741066054), Lot REKY2420
The devices are indicated for short-term vascular access for hemodialysis and related treatments.
What You Should Do
No specific consumer action steps are provided in the recall notice.
Why This Matters
This Class II recall involves devices distributed across the United States and internationally, linked to a supplier manufacturing issue with lidocaine ampoules.
Source
FDA recall number Z-2660-2026
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,839 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to August 8, 2026.
Frequently Asked Questions
Common questions about this FDA recall.